Amgen Inc. (NASDAQ:AMGN) Shares Sold by Global Assets Advisory LLC

Global Assets Advisory LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 58.7% in the 4th quarter, Holdings Channel reports. The firm owned 1,072 shares of the medical research company’s stock after selling 1,523 shares during the quarter. Global Assets Advisory LLC’s holdings in Amgen were worth $278,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Beck Mack & Oliver LLC lifted its position in shares of Amgen by 0.7% during the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock valued at $1,205,000 after acquiring an additional 34 shares during the period. Blossom Wealth Management raised its holdings in Amgen by 3.5% during the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock worth $284,000 after purchasing an additional 37 shares during the last quarter. Zullo Investment Group Inc. boosted its position in Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after purchasing an additional 37 shares in the last quarter. Trillium Asset Management LLC grew its holdings in Amgen by 4.2% in the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 37 shares during the last quarter. Finally, Evermay Wealth Management LLC increased its position in shares of Amgen by 1.5% in the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company’s stock valued at $691,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on AMGN shares. Citigroup reiterated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Mizuho increased their price target on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday. Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research note on Friday, May 2nd. Bank of America boosted their price target on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $310.23.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,707 shares of company stock worth $12,819,342 over the last ninety days. 0.69% of the stock is owned by company insiders.

Amgen Trading Down 2.3 %

AMGN stock opened at $265.86 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market cap of $142.94 billion, a price-to-earnings ratio of 35.21, a PEG ratio of 2.63 and a beta of 0.51. The business has a fifty day simple moving average of $296.08 and a 200-day simple moving average of $289.86. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.96 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.58%. Amgen’s dividend payout ratio (DPR) is 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.